Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Endeavor Biomedicines, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07454291CT.gov A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants | — | Recruiting | — | — | — |
NCT05817240CT.gov A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects | — | Completed | — | — | — |
NCT04968574CT.gov A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Idiopathic Pulmonary Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Taladegib (this asset) | Endeavor Biomedicines, Inc. | P2 | CCC · 55 |
| Pirfenidone | Endeavor Biomedicines, Inc. | P4 | A |
| Acetylcysteine | Endeavor Biomedicines, Inc. | P4 | BBB |
| Nintedanib | Mannkind Corporation | P4 | BBB |
| hsk44459 | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| Prednisone | Fondation Hôpital Saint-Joseph | P3 | BB |
| Nerandomilast | Boehringer Ingelheim | P3 | BB |
| Sildenafil | Hoffmann-La Roche | P4 | BB |
| hec585 | Sunshine Lake Pharma Co., Ltd. | P3 | B |
+42 more in the Idiopathic Pulmonary Fibrosis cohort
Other indications for Taladegib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P1/2 | CC · 45 |
| Metastatic Neoplasm | — | P1 | CC · 42 |
| Cancer | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Taladegib in Idiopathic Pulmonary Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/taladegib-idiopathic-pulmonary-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →